Company intelligence / Profile preview

Aurora Medbiochem

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Aurora Medbiochem is a clinical-stage biotechnology company dedicated to the discovery and development of next-generation small molecule drugs for the treatment of cancer and other serious diseases. The company utilizes a proprietary drug discovery engine to target high-value biological mechanisms, specifically focusing on the DNA damage response (DDR) and the RAS/MAPK signaling pathway. Its lead candidate, AMB-101, is a potent and selective USP1 inhibitor currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors. By integrating structural biology and medicinal chemistry, Aurora Medbiochem aims to provide transformative therapies for patients with unmet medical needs globally.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Aurora Medbiochem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aurora Medbiochem.

Explore the full profile